Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer in the UK

被引：0
|
作者：
Karnon, J
Delea, TE
Papo, NL
Barghout, V
Thomas, SK
Johnston, SR
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Policy Anal Inc, Brookline, MA USA
[3] Novartis Pharmaceut UK Ltd, Camberley, England
[4] Novartis Pharmaceut Corp, Florham Pk, NJ USA
[5] Novartis Pharmaceut Corp, E Hanover, NJ USA
[6] Royal Marsden Hosp, London SW3 6JJ, England
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67270-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A43 / A43
页数：1
相关论文
共 50 条
  • [41] Letrozole is cost-effective versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: BIG-1-98
    Karnon, J.
    Johnston, S. R. D.
    Delea, T.
    Barghout, V.
    Thomas, S.
    Papo, N. L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 96 - 96
  • [42] Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer
    Hillner, BE
    CANCER, 2004, 101 (06) : 1311 - 1322
  • [43] Cost-Effectiveness of Letrozole in the Extended Adjuvant Treatment of Women with Early Breast Cancer
    Khalid El Ouagari
    Jon Karnon
    Thomas Delea
    Willena Talbot
    Jane Brandman
    Breast Cancer Research and Treatment, 2007, 101 : 37 - 49
  • [44] Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer
    El Ouagari, Khalid
    Karnon, Jon
    Delea, Thomas
    Talbot, Willena
    Brandman, Jane
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (01) : 37 - 49
  • [45] Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis
    Huang, Xiaoting
    Liu, Yiwei
    Lin, Shen
    Wang, Hang
    Deng, Yujie
    Rao, Xin
    Guo, Xianzhong
    Jiang, Xinchan
    Weng, Xiuhua
    Huang, Pinfang
    INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 2023, 35 (02)
  • [46] Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen TherapyThe UK Perspective
    Jonathan Karnon
    Thomas Delea
    Stephen R. D. Johnston
    Robert Smith
    Jane Brandman
    Jennifer Sung
    Paul E. Goss
    PharmacoEconomics, 2006, 24 : 237 - 250
  • [47] COST-EFFECTIVENESS OF LETROZOLE AND OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER USING UPDATED SURVIVAL DATA FROM THE BIG 1-98 AND ATAC TRIALS: A UK PERSPECTIVE
    Karnon, J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
  • [48] International comparison of the cost-effectiveness of 5 years letrozole or anastrozole compared to 5 years tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Belgium, Canada, UK, and US analyses
    Kaura, S.
    Karnon, J.
    di Trapani, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Reflecting time dependency in hazard rates to analyse the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor-positive (HR+) postmenopausal women: The U.S. perspective
    Karnon, J.
    Mody-Patel, N.
    Kaura, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Cost-effectiveness of five years of extended adjuvant letrozole in postmenopausal women with early breast cancer who have completed five years of adjuvant tamoxifen.
    Delea, TE
    Karnon, J
    Smith, RE
    Brandman, J
    Sung, JC
    Goss, PPE
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S58 - S58
12345